Her Metabolic Health · Shared Agency Framework (SAF) Clinical Protocol 02

SAF Protocol 02: GLP-1 Gastric Emptying, Ileal Brake Mechanics, Vagal Afferent Signaling & Bristol Stool Calibration

Mechanistic neuro-gastroenterology protocol distinguishing therapeutic GLP-1 gastric transit delay and vagus nerve (CN X) mechanoreceptor fullness from defensive nausea, sulfur eructation, and colonic hypomotility using meal volume pacing, nutrient sequencing, and daily Bristol Stool Form Scale (Types 1 to 7) calibration.

1. Operationalizing the Physiological Delay: The Ileal Brake

In the Shared Agency Framework (SAF), we treat gastrointestinal transit as a shared clinical dashboard. The Ileal Brake is the body's native neuro-endocrine feedback reflex in which nutrients reaching the distal ileum stimulate L-cells to secrete endogenous GLP-1 and Peptide YY (PYY), slowing proximal gastric emptying and intestinal motility to optimize nutrient absorption (Maljaars et al., Am J Clin Nutr 2008; PMID: 17928588; Layer et al., PMID: 3753891).

When a patient initiates pharmacologic GLP-1 or dual GIP/GLP-1 receptor agonist therapy, this delay in gastric emptying is substantially amplified. The SAF objective is for clinician and patient to calibrate the therapeutic window between Comfortable Early Satiety and Gastrointestinal Distress.

2. Enteric Receptor Density & Neural Adaptation (Tachyphylaxis)

The stomach and vagal afferent pathways act as strategic data processors. Understanding GLP-1 receptor distribution and pharmacokinetic adaptation allows the SAF team to anticipate and prevent avoidable distress:

Vagal & Pyloric Signaling: GLP-1 receptors expressed on vagal nodose ganglion neurons and gastric myenteric plexuses reduce antral contractions and increase pyloric sphincter tone, retaining chyme in the stomach longer.
Anticipating Tachyphylaxis: Controlled physiological studies demonstrate that pharmacologic slowing of gastric emptying is strongest during initial dose induction and early dose escalations, attenuating over time via vagal receptor tachyphylaxis (Nauck et al., Diabetes 2011; PMID: 21430086), whereas central hypothalamic appetite regulation remains durable.
Dose-Escalation Implication:Per FDA prescribing labels for semaglutide and tirzepatide, gradual 4-week dose escalation exists specifically to improve gastrointestinal tolerability. If a patient is experiencing active nausea on her current dose, holding at that dose bracket allows enteric adaptation before any increase.

3. The Satiety-to-Defense Shift on the Vagus Nerve

The Enteric Nervous System communicates continuously with the brainstem nucleus tractus solitarius (NTS) via the Vagus Nerve. Under SAF, vagal sensations are logged as primary clinical telemetry:

Vagal Signal State	Physiological Mechanism	SAF Partnership Action
Therapeutic Satiety	Mild gastric wall stretch activates vagal mechanoreceptors, signaling comfortable fullness after smaller meal volumes.	Stop eating at the first satiety signal; retire plate-completion guilt; prioritize protein first.
Vagal Defense Alert (Nausea / Reflux)	Excessive meal volume or high dietary fat density over-distends the delayed stomach, shifting vagal signaling from Satiety to Defense.	Execute "Pause and Recalibrate": switch to low-fat, small-volume liquid/hydrolyzed protein intakes; separate fluids from solids by 30 minutes; hold dose escalation.
Colonic Transit Slowing	Reduced gastrocolic reflex and decreased fluid intake slow colonic transit (Bristol Stool Form Scale Types 1 to 2).	Track 7-day Bristol Stool Form score; optimize water + electrolyte intake and discuss magnesium citrate (with renal check) with prescriber.

4. Tactical Management of the "Second Brain"

Sensation as Shared Data: Nausea is predominantly dose- and meal-volume related. Using the printable SAF Second Brain Calibration Log (PDF), the patient records intake form (solid vs. liquid), fat density, and Bristol Stool Form score over 7 days to share with her prescriber.
Strategic Liquid Nutrient Delivery: During the 24 to 48 hours post-injection when plasma drug concentration peaks (Cmax), high-bioavailability liquid protein isolates deliver essential amino acids without overwhelming delayed gastric clearance.
Protein-First Sequencing: Consume protein first to secure the 2.5g-3.0g leucine threshold, cooked vegetables/soluble fiber second, and complex carbohydrates last.

Interactive Patient Self-Check · Zero PHI Stored

Interactive "Second Brain" Vagal Satiety vs. Nausea Triage

Distinguish healthy Ileal Brake mechanical fullness from vagal defense signals (nausea, reflux, sulfur burps, or Bristol Type 1-2 slow transit):

Primary GI / Vagal Sensation Recent Meal Composition

Your Vagal & Enteric Calibration Protocol

Result: Vagal Mechanoreceptor Defense Triggered (24-48h Peak)
-------------------------------------------------------------
1. Mechanism: At 24-48 hours post-injection, GLP-1 plasma concentration peaks. Dietary fat or large meal volume lingers in the stomach via the Ileal Brake (PMID: 17928588), over-stretching vagal mechanoreceptors.
2. Immediate Fix: Switch to protein-first micro-meals (<1.25 cups volume), keep dietary fat <15g per meal during peak window, and separate fluids by 30 minutes before/after meals.
3. Next Tool: Log 7 days in the Second Brain Motility Log (Tool 04).

Open Full Motility Log (Tool 04) → Printable Log PDF →

5. Primary Citations & Downloads

Maljaars PW, Peters HP, Mela DJ, Masclee AA. Ileal brake: a sensible food target for appetite control. A review. Physiol Behav / Am J Clin Nutr. 2008;95(3):271-281. (PMID: 17928588)
Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid secretion in humans. Dig Dis Sci. 1995 / 1986. (PMID: 3753891)
Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565. (PMID: 21430086)

Download SAF Protocol 02 (PDF) Download Second Brain Log (PDF) Next: SAF Doc 03 (Sarcopenia Prevention) →

Shared Agency Framework (SAF) · Complete 5-Part Patient Biological Series

← The 3-Pillar Framework Hub 01. Cortisol-Willpower Loop 02. Gastric Emptying & Second Brain 03. Sarcopenia & Muscle Defense 04. Dopamine & Food Noise 05. Set Point & Plateaus Open 5 Patient Calculators →

Clinical Safety Protocol · Same-Day Escalation

When to Call Your Prescriber the Same Day

Mild satiety fullness and gradual bowel changes can be managed with food sequencing and hydration, but the following symptoms require same-day prescriber evaluation or urgent medical care:

Persistent Vomiting: Unable to keep liquids down for more than 24 hours.
Severe Upper Belly Pain: Sharp or persistent pain in the upper abdomen, especially if radiating to your back (requires immediate evaluation for pancreatitis or gallbladder disease).
Obstipation with Vomiting: No bowel movement accompanied by abdominal swelling or vomiting.
Acute Dehydration Signs: Dizziness upon standing, confusion, racing pulse, or dark/absent urine (risk of acute kidney injury).
Low Mood or Self-Harm Thoughts: New or worsening depression, persistent emotional flatness (anhedonia), or any thoughts of self-harm. Call your prescriber the same day, or call/text 988 (Suicide & Crisis Lifeline) or 911 in an emergency.

SAF Guide 02 Clinical Specification Matrix (EAV)

Ileal Brake, Vagal Mechanoreceptors & Bristol Motility Targets

Enteric System Entity	Physiological Mechanism (Citation)	Target / Red-Flag Threshold	Shared Agency Intervention
The Ileal Brake	Distal L-cell GLP-1 & PYY secretion slows pyloric emptying (PMID: 17928588)	Prolonged gastric residence on Days 1-3 post-injection	Sequence lean protein first; cap dietary fat at <15g/meal on peak days
Vagal Stretch Receptors	CN X afferents transmit gastric wall tension to the brainstem NTS	Gentle fullness (score 3-5) vs. defensive nausea/reflux (score 7-10)	Separate bulk fluids by 30 minutes before/after solid protein meals
Receptor Tachyphylaxis	Continuous GLP-1R stimulation attenuates acute gastric slowing over 8-16 weeks (PMID: 21430086)	Return of comfortable gastric emptying does NOT mean drug failure	Verify central satiety via Tool 05: Signal Volume Log
Colonic Transit (Bristol Scale)	Slowed enteric peristalsis increases colonic water reabsorption	Target: Bristol Stool Types 3 to 4 daily (Red flag: Type 1-2 >3 days)	Log daily in Tool 04: Second Brain Motility Log

Mechanistic Paradigm Shift · Side-Effect Suffering vs. Vagal Calibration

Legacy "Just Push Through Nausea" vs. Shared Agency Second Brain Calibration

Legacy Unassisted Telehealth Model

"Nausea Means the Drug Is Working"

Leaves patients to suffer through preventable reflux, vomiting, or severe constipation, or prematurely escalates the dose on a rigid 4-week calendar before the enteric nervous system has calibrated.

Shared Agency Framework (SAF Guide 02)

Read Vagal Signals & Sequence Meals

Interprets nausea as a mechanical stretch-receptor warning. Uses protein-first food sequencing, 30-minute fluid separation, and Bristol Types 3-4 tracking to keep digestion comfortable and sustainable.

Direct-Answer Clinical Knowledge Graph (GEO FAQ)

Frequently Asked Clinical & Biomarker Questions

Standalone, peer-reviewed clinical answers structured for patients, prescribers, and clinical decision support.

Why do GLP-1 receptor agonists cause nausea and sulfur burps after high-fat or large-volume meals?

GLP-1 receptor agonists activate the ileal brake and vagal efferent pathways that slow antroduodenal motility and pyloric opening. High-fat or large-volume solid meals remain in the stomach longer, triggering gastric stretch-receptor vagal distress signals and microbial fermentation (hydrogen sulfide eructation).

What is the target Bristol Stool Form Scale range on Semaglutide or Tirzepatide?

The target range is Bristol Stool Form Scale Types 3 to 4 (smooth, soft, easily passed stool). Bristol Types 1 to 2 indicate slow colonic transit and dehydration requiring immediate electrolyte-backed hydration (2.5 to 3.0 L/day), soluble fiber calibration, or osmotic magnesium citrate support.

How should meals be sequenced to prevent GLP-1 nausea while hitting protein targets?

Eat 25 to 35 grams of lean, easily digestible protein first, followed by cooked or soluble-fiber produce, and keep added dietary fats moderate during peak Cmax days (Days 1 to 3 post-injection). Separate large fluid boluses from solid meals by 20 to 30 minutes if early gastric fullness occurs.

When is abdominal pain or vomiting on a GLP-1 an urgent same-day medical red flag?

Persistent vomiting preventing liquid intake for more than 24 hours, severe upper abdominal pain radiating to the back (potential pancreatitis or cholelithiasis), or absence of bowel movements with abdominal distension and vomiting require same-day prescriber evaluation or emergency care.